American Stocks Videos
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

American Stocks Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
American StocksVideosPharma and Airline Stocks Move on Earnings and Weather
American StocksOptions & Derivatives

Pharma and Airline Stocks Move on Earnings and Weather

•February 23, 2026
0
tastylive (tastytrade)
tastylive (tastytrade)•Feb 23, 2026

Why It Matters

The reaction to trial results and storm‑driven airline disruptions creates immediate trading opportunities, prompting investors to shift from shorting to buying dips in pharma and airline stocks.

Key Takeaways

  • •Novo Nordisk drops 16% after weight‑loss trial miss
  • •Hims sees buying interest ahead of earnings release today
  • •Delta Airlines down 4% despite broader airline sell‑off
  • •Trader sells March $65 put on Delta, collecting $278
  • •Strategy focuses on buying dips, not shorting losing stocks

Summary

The video highlights two distinct market drivers on February 23: a disappointing weight‑loss trial from Novo Nordisk that sent its shares tumbling, and a severe East Coast storm that pressured airline stocks.

Novo Nordisk fell 16% after its experimental obesity drug underperformed Lilly’s, prompting the hosts to avoid shorting the stock and instead take a long position in Hims (HIMS), which is set to report earnings after the close. Meanwhile, the airline sector saw American and United slide over 5%, while Delta dropped only 4% despite congestion and technical outages.

Liz emphasized, “I’m not shorting Novo, I’m getting long HIMS,” and outlined a bullish put‑sell on Delta: a March $65 put collected $278 against $1,175 of margin, offering upside potential down to $62.50. The trade is presented as a high‑probability dip‑buy.

These moves suggest traders are capitalizing on short‑term volatility—using clinical‑trial news and weather‑related disruptions to rebalance exposure, favoring dip purchases over outright shorts, which could shape near‑term positioning in both pharma and airline equities.

Original Description

In today’s Market Movers segment, Liz and Jenny break down major stock moves in pharmaceuticals and airlines and discuss how traders may approach the volatility.
Novo Nordisk fell sharply after weight loss drug trial results underperformed a competitor, while HIMSS gained attention ahead of earnings. The discussion covers alternative ways to express directional opinions without directly shorting the headline stock.
Airline stocks also moved lower following severe weather disruptions on the East Coast, with American, United, and Delta all under pressure. The segment explores a bullish short put strategy in Delta Airlines, explaining the structure, capital required, and potential return profile.
This is a real-time look at how traders assess risk, evaluate probability, and structure defined strategies during periods of increased volatility.
Helpful links:
tastylive: https://www.tastylive.com/
FREE tasytlive Newsletters: https://info.tastylive.com/newsletters
FREE Options Strategy Guide: https://tinyurl.com/bp9ms763
Follow tastylive on X (Twitter): https://x.com/tastyliveshow
#OptionsTrading #DayTrading #LiveTrading #FuturesTrading #StockMarket #TradingEducation #Investing #MarketAnalysis #TradingStrategy #FinancialEducation
tastylive is a real financial network, producing hours of live programming every day. Follow along as our experts navigate the markets, provide actionable trading insights, and teach you how to trade. With over 120 original segments, and over 25 personalities, we’ll help you take your trading to the next level, whether you are new to trading or a seasoned veteran.
tastylive content is created, produced, and provided solely by tastylive, Inc. (“tastylive”) and is for informational and educational purposes only. It is not, nor is it intended to be, trading or investment advice or a recommendation that any security, futures contract, digital asset, other product, transaction, or investment strategy is suitable for any person. Trading securities, futures products, and digital assets involve risk and may result in a loss greater than the original amount invested. Investment information provided may not be appropriate for all investors and is provided without respect to individual investor financial sophistication, financial situation, investing time horizon or risk tolerance. Options, futures, and futures options are not suitable for all investors. Prior to trading securities, options, futures, or futures options, please read all applicable risk disclosures, including, but not limited to, the Characteristics and Risks of Standardized Options Disclosure and the Futures and Exchange Traded Options Risk Disclosure Statement found at https://tastytrade.com/disclosures/.
Past performance is not indicative of future results. Performance is not presented net of all commissions, fees, and expenses. Multi-leg option strategies incur higher transaction costs than single leg trades as they involve multiple commission charges. Examples provided are for illustrative, informational, and educational purposes only and are not intended to be reflective of results you can expect to achieve. Supporting documentation for any claims (including claims made on behalf of options programs), comparisons, statistics, or other technical data, if applicable, will be supplied upon request.
tastylive, through its content, financial programming or otherwise, does not provide investment or financial advice or make investment recommendations. tastylive is not a licensed financial adviser, registered investment adviser, or a registered broker-dealer.
0

Comments

Want to join the conversation?

Loading comments...